Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;48(3):2833-2841.
doi: 10.1007/s11033-021-06285-1. Epub 2021 Mar 25.

PARP overactivation in neurological disorders

Affiliations
Review

PARP overactivation in neurological disorders

Vijay Kumar Arruri et al. Mol Biol Rep. 2021 Mar.

Abstract

Poly (ADP-ribose) polymerases (PARPs) constitute a family of enzymes associated with divergent cellular processes that are not limited to DNA repair, chromatin organization, genome integrity, and apoptosis but also found to play a crucial role in inflammation. PARPs mediate poly (ADP-ribosylation) of DNA binding proteins that is often responsible for chromatin remodeling thereby ensure effective repairing of DNA stand breaks although during the conditions of severe genotoxic stress PARPs direct the cell fate towards apoptotic events. Recent discoveries have pushed PARPs into the spotlight as targets for treating cancer, metabolic, inflammatory and neurological disorders. Of note, PARP-1 is the most abundant isoform of PARPs (18 member super family) which executes more than 90% of PARPs functions. Since oxidative/nitrosative stress actuated PARP-1 is linked to vigorous DNA damage and wide spread provocative inflammatory response that underlie the aetiopathogenesis of different neurological disorders, possibility of developing PARP-1 inhibitors as plausible neurotherapeutic agents attracts considerable research interest. This review outlines the recent advances in PARP-1 biology and examines the capability of PARP-1 inhibitors as treatment modalities in intense and interminable diseases of neuronal origin.

Keywords: Neuroinflammation; Neurological disorders; PARP-1; PARP1 inhibitors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Chambon P, Weill J, Mandel P (1963) Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43 - PubMed
    1. Amé JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. BioEssays 26:882–893 - PubMed
    1. Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS et al (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192–222 - PubMed
    1. de Murcia G, De Murcia JM (1994) Poly (ADP-ribose) polymerase:a molecular nick sensor. Trends Biochem Sci 19:172–176 - PubMed
    1. Berger N, Berger S, Catino D, Petzold S, Robins R (1985) Modulation of nicotinamide adenine dinucleotide and poly (adenosine diphosphoribose) metabolism by the synthetic. J Clin Investig 75:702–709 - PubMed

Substances

LinkOut - more resources